QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum
- PMID: 19477134
- PMCID: PMC3914672
- DOI: 10.1016/j.bmc.2009.05.010
QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum
Abstract
Maximal inhibition (I(max)) of the agonist effect is an important pharmacological property of inhibitors that interact with multiple receptor subtypes that are activated by the same agonist and which elicit the same functional response. This report represents the first QSAR study on a set of 66 mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating nicotine-evoked dopamine release, conducted using multi-linear regression (MLR) and neural network (NN) analysis with the maximal inhibition (I(max)) values of the antagonists as target values. The statistical results for the generated MLR model were: r(2)=0.89, rmsd=9.01, q(2)=0.83 and loormsd=11.1; the statistical results for the generated NN model were: r(2)=0.89, rmsd=8.98, q(2)=0.83 and loormsd=11.2. The maximal inhibition values of the compounds exhibited a good correlation with the predictions made by the QSAR models developed, which provide a basis for rationalizing selection of compounds for synthesis in the discovery of effective and selective second generation inhibitors of nAChRs mediating nicotine-evoked dopamine release.
Figures



Similar articles
-
QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release.Bioorg Med Chem. 2006 May 1;14(9):3017-37. doi: 10.1016/j.bmc.2005.12.036. Epub 2006 Jan 20. Bioorg Med Chem. 2006. PMID: 16431111
-
Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.Bioorg Med Chem Lett. 2007 Dec 15;17(24):6701-6. doi: 10.1016/j.bmcl.2007.10.062. Epub 2007 Oct 22. Bioorg Med Chem Lett. 2007. PMID: 17977723 Free PMC article.
-
Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.Bioorg Med Chem Lett. 2007 Dec 15;17(24):6734-8. doi: 10.1016/j.bmcl.2007.10.052. Epub 2007 Oct 18. Bioorg Med Chem Lett. 2007. PMID: 18029180 Free PMC article.
-
Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.Bioorg Med Chem Lett. 2008 Nov 1;18(21):5753-7. doi: 10.1016/j.bmcl.2008.09.084. Epub 2008 Sep 26. Bioorg Med Chem Lett. 2008. PMID: 18851914 Free PMC article.
-
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.J Med Chem. 1997 Dec 19;40(26):4169-94. doi: 10.1021/jm970377o. J Med Chem. 1997. PMID: 9435889 Review. No abstract available.
Cited by
-
Improved Prediction of Blood-Brain Barrier Permeability Through Machine Learning with Combined Use of Molecular Property-Based Descriptors and Fingerprints.AAPS J. 2018 Mar 21;20(3):54. doi: 10.1208/s12248-018-0215-8. AAPS J. 2018. PMID: 29564576 Free PMC article.
-
Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches.Bioorg Med Chem. 2014 Jan 1;22(1):538-49. doi: 10.1016/j.bmc.2013.10.053. Epub 2013 Nov 8. Bioorg Med Chem. 2014. PMID: 24290065 Free PMC article.
-
Wide-Antimicrobial Spectrum of Picolinium Salts.Molecules. 2020 May 11;25(9):2254. doi: 10.3390/molecules25092254. Molecules. 2020. PMID: 32403238 Free PMC article.
-
Nicotinic receptor antagonists as treatments for nicotine abuse.Adv Pharmacol. 2014;69:513-51. doi: 10.1016/B978-0-12-420118-7.00013-5. Adv Pharmacol. 2014. PMID: 24484986 Free PMC article. Review.
References
-
- Ericon N. US Department of Justice. 2001 May;17
-
- Lam CY, Minnix JA, Robinson JD, Cinciripini PM. J Natl Compr Canc Netw. 2006;4:583. - PubMed
-
- Glover ED, Rath JM. Expert Opin Pharmacother. 2007;8:1757. - PubMed
-
- Potts LA, Garwood CL. Am J Health-Syst Pharm. 2007;64:1381. - PubMed
-
- Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. N Eng J Med. 1997;337:1195. - PubMed
- Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto JL, Daughton DM, Doan K, Fiore MC, Baker TBA. N Eng J Med. 1999;340:685. - PubMed
- Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G. DeVeaugh-Geiss Psychopharmacol (Berl) 2000;148:33. - PubMed
- Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Clin Pharmacol Ther. 1994;56:86. - PubMed
- Rose JE, Westman EC, Behm FM, Johnson MP, Goldberg JS. Pharmacol Biochem Behav. 1999;62:165. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Chemical Information
Miscellaneous